Skip to main content
Premium Trial:

Request an Annual Quote

Patent for Editing

The Broad Institute was awarded a patent last week covering its engineered CRISPR-Cas9 system, a press release from the institute says.

According to US Patent No. 8,697,359, the "invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products." It also mentions how the tool could be used to treat a number of diseases.

“The CRISPR-Cas9 system is an extraordinary, powerful tool," Eric Lander, the director of the Broad, says in a statement. "The ability to edit a genome makes it possible to discover the biological mechanisms underlying human biology and, potentially, to treat certain human diseases."

The researcher listed on the patent is Feng Zhang, a core member of the Broad and co-founder of Editas Medicine, notes MIT's Technology Review.

Lander adds that the Broad will make the technology available to researchers around the world.

Still, Chelsea Loughran, an intellectual property litigation lawyer, tells Tech Review how this will affect people already using CRISPR is unclear. A Broad spokesperson echoed Lander's remark that the tool would be widely available, though said that specific licensing details weren't available.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.